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Abstract
Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that persists lifelong in the host. In ,4% of infected people,
HTLV-1 causes a chronic disabling neuroinflammatory disease known as HTLV-1-associated myelopathy/tropical spastic
paraparesis (HAM/TSP). The pathogenesis of HAM/TSP is unknown and treatment remains ineffective. We used gene
expression microarrays followed by flow cytometric and functional assays to investigate global changes in blood
transcriptional profiles of HTLV-1-infected and seronegative individuals. We found that perturbations of the p53 signaling
pathway were a hallmark of HTLV-1 infection. In contrast, a subset of interferon (IFN)-stimulated genes was over-expressed
in patients with HAM/TSP but not in asymptomatic HTLV-1 carriers or patients with the clinically similar disease multiple
sclerosis. The IFN-inducible signature was present in all circulating leukocytes and its intensity correlated with the clinical
severity of HAM/TSP. Leukocytes from patients with HAM/TSP were primed to respond strongly to stimulation with
exogenous IFN. However, while type I IFN suppressed expression of the HTLV-1 structural protein Gag it failed to suppress
the highly immunogenic viral transcriptional transactivator Tax. We conclude that over-expression of a subset of IFN-
stimulated genes in chronic HTLV-1 infection does not constitute an efficient host response but instead contributes to the
development of HAM/TSP.
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Introduction
HTLV-1 is an exogenous retrovirus that is widespread in the
tropics and subtropics [1,2]. Chronic infection is characterised by
a strong humoral and cellular immune response against the virus
[3].
Whilst the majority of HTLV-1 carriers efficiently control the
infection and remain clinically asymptomatic lifelong, some 1–4%
develop a neurodegenerative inflammatory disorder known as
HAM/TSP [1]. Here, mononuclear cell infiltrates in the central
nervous system are associated with myelin and axonal destruction
[1,4]. Clinically, patients present with multiple sclerosis-like
symptoms including progressive spastic paraparesis, sensory loss
and disturbances of bladder or bowel function [1,5]. The sequence
and nature of the events that lead to the observed neuronal damage
in HAM/TSP are not known and because of the lack of a suitable
animal model a direct investigation of pathogenic mechanisms is not
possible. Thus, clinical management of HAM/TSP is unsatisfactory
and current treatment remains only palliative.
To date, the strongest correlate of risk of HAM/TSP remains a
high HTLV-1 proviral load [6], i.e. the percentage of peripheral
blood mononuclear cells that carry the provirus. The proviral
load can differ among individuals by 1000-fold; the mean proviral
load is ,15-fold higher in patients with HAM/TSP than in
asymptomatic HTLV-1 carriers (ACs) [6]. However, a significant
proportion of infected individuals who present with high HTLV-1
proviral loads never develop the inflammatory disease, suggesting
that additional factors contribute to the pathogenesis of HAM/TSP.
Although other risk factors have been proposed, few differ
systematically between ACs and patients with HAM/TSP after
normalisation for proviral load: the frequency of certain lympho-
cyte subsets (HTLV-1-specific CD4+ T cells [7]; FoxP3+CD4+ T
cells [8]; natural killer (NK) cells [9]); the level of expression of
HTLV-1 genes [10] and the pattern of integration of the HTLV-1
provirus in the host cell genome [11]. However, the contribution of
each of these factors to the pathology of HAM/TSP is not known.
Blood transcriptional profiles have revealed previously unsus-
pected pathways of pathogenesis in autoimmune and infectious
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diseases [12,13]. Exposure to host or pathogen-derived immuno-
genic factors trigger changes in gene expression in peripheral
blood leukocyte populations that reflect the host immune response
mounted against pathogens as well as pathologic conditions of the
immune system [14]. Thus, patient blood samples provide an
easily accessible source of immunophenotypic information and are
of particular value in HTLV-1 infection, in which CD4+ T cells
constitute the major viral reservoir [15]. Previous studies on gene
expression in HTLV-1 infection have focused on specific cell
subpopulations (HTLV-1-infected cells, CD4+ T cells, CD8+ T
cells) [16–21]. In contrast, whole blood studies integrate gene
expression profiles of all leukocytes. Thus, the resulting transcrip-
tional profiles provide a comprehensive overview of the status of
the immune system and associated pathological changes.
In this study, we aimed to identify the principal biological
pathways and cell types that are deregulated in HTLV-1 infection
and HAM/TSP by quantifying and analyzing differences in blood
gene expression patterns of HTLV-1-infected individuals and
seronegative controls. Unexpectedly, although the class I-restricted
T cell response plays a pivotal role in controlling viral replication
and risk of disease [22,23], the outstanding differences in the
transcriptional patterns lay in IFN-stimulated genes. We found
that over-expression of a distinct subset of IFN-stimulated genes –
a ‘transcriptional signature’ – was associated with presence of the
inflammatory disease and positively correlated with clinical
severity of HAM/TSP. This IFN-inducible transcriptional signa-
ture was absent in patients with multiple sclerosis, suggesting
distinct pathogenetic pathways in the two diseases despite their
clinical similarities. We conclude that IFNs do not efficiently
control chronic HTLV-1 infection but may instead contribute to
HAM/TSP pathogenesis. Our results identify IFN signaling as a
key factor and a novel therapeutic target in HAM/TSP.
Results
The blood transcriptional signature of HTLV-1 infection
Gene expression profiles were generated from blood samples taken
from patients with HAM/TSP, ACs and HTLV-1-seronegative
individuals (Table S1 A). To identify a transcriptional signature that
reflects HTLV-1 infection per se irrespective of clinical phenotype,
we compared gene expression profiles between uninfected and all
HTLV-1-positive individuals (Figure S1). HTLV-1 infection resulted
in altered blood expression levels of 542 genes (Table S2). The
majority of identified gene products were involved in cell cycle
control, cell proliferation and anti-viral immune responses: the most
strongly associated cellular process was the p53 signaling pathway
(Figure 1 A). In accordance with previous in vitro findings [24,25],
mediators of cell cycle arrest and apoptosis were over-represented in
patients with HAM/TSP while expression of molecules in the DNA
damage response pathways was inhibited (Figure 1 B–D).
The blood transcriptional signature of HAM/TSP
pathology
Differential gene expression in HTLV-1 infection is driven both
directly, by the viral infection of T cells (in proportion to the
proviral load, i.e. the percentage of HTLV-1-infected PBMCs),
and by the presence or absence of the inflammatory disease
HAM/TSP. To identify genes associated with HAM/TSP whose
expression varied independently of proviral load, we subdivided
ACs into two groups: those with high proviral load ($1% PBMCs)
or low proviral load (,1% PBMCs). A distinct 80-gene blood
transcriptional signature in patients with HAM/TSP was
identified by non-parametric group comparison (Table S3).
Hierarchical clustering analysis based on similarity in gene
expression grouped individuals into two clusters associated with
presence or absence of the inflammatory disease (two-tailed
Fisher’s exact test: P,0.0001) but not gender, age and ethnicity
(Figure 2 A).
Replication of the HAM/TSP transcriptional signature in a
validation cohort
To validate the HAM/TSP transcriptional signature identified
in the first cohort (training set), we applied the list of 80 genes to a
second, independently collected and processed patient cohort (test
set; Figure 2 B; Table S1 B). Based on the expression levels of these
80 genes, k-nearest neighbor class prediction identified patients
with HAM/TSP in the test set with a sensitivity of 70% and
specificity of 92%; a support vector machine approach gave
similar results (Table S4).
Two ACs in the training set and three in the test set were
misclassified as HAM/TSP, representing 10% and 17% of the
respective asymptomatic cohorts. However, three of these five
individuals had previously presented with urticaria and urinary
urgency, which are associated with onset of HAM/TSP, and with
episodes of uveitis, and other inflammatory conditions associated
with HTLV-1 [26]. These observations also suggest that the
transcriptional signature is specifically associated with HTLV-1-
associated inflammatory disease, rather than viral infection alone.
Transcriptional changes in the 80-gene signature were quantified
using the ‘weighted molecular distance to health’ (WMDH) statistic
[12] which measures the difference in expression of specified genes
between patients and controls. The WMDH was significantly
higher in patients with HAM/TSP than in ACs with high or low
proviral load, confirming the association between the transcription-
al signature and the inflammatory disease (Figure 2 C).
Intensity of the blood transcriptional signature correlates
with clinical severity of HAM/TSP
Two patients diagnosed with HAM/TSP clustered with
uninfected and asymptomatic individuals in the test set (Figure 2
B: filled triangle, empty square). To test whether this observation
Author Summary
Infection with the Human T Lymphotropic virus is
widespread in the tropics and subtropics, where it causes
a chronic disabling disease of the nervous system
abbreviated as HAM/TSP. There is no effective treatment
available for HAM/TSP, because it is not understood how
the virus causes the neuronal damage that results in the
clinical symptoms of weakness and paralysis of the legs.
Here, we compared the frequencies of cell populations and
gene expression profiles from diseased and asymptomatic
HTLV-1 carriers to identify abnormalities in biological
pathways that cause HAM/TSP. We discovered a distinct
group of genes that is over-expressed in white blood cells
in patients with HAM/TSP, but not asymptomatic HTLV-1
carriers or patients with the clinically similar disease
multiple sclerosis. The expression of these genes is
induced by interferons, a group of anti-viral proteins that
are usually beneficial to the host but can also cause
inflammation. We also found that interferons did not
efficiently suppress HTLV-1 protein expression in vitro. We
conclude that interferons do not control chronic HTLV-1
infection but instead contribute to the development of
HAM/TSP. Our study provides new insights into the
development of HTLV-1-associated diseases and opens
new areas of therapeutic intervention.
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reflected heterogeneity in disease severity, we grouped patients
according to their performance in the 10-meter timed walk, a test
of the patient’s mobility, on the day the blood sample was taken
(Figure 2 D). Indeed, the two outlier patients had only mild or
moderate impairment of mobility. In the whole cohort, the
WMDH was significantly greater in patients who took .30 s to
walk 10 m or required wheelchairs compared with less disabled
HAM/TSP patients (healthy controls ,8 s). Thus, the degree of
molecular perturbation of the transcriptional signature reflected
the clinical severity of HAM/TSP (Figure 2 D).
The gene expression profiles of HAM/TSP and multiple
sclerosis are distinct
Clinically, HAM/TSP closely resembles certain forms of
multiple sclerosis; both diseases show neurological abnormalities
due to axonal lesions in the spinal cord and brain [1,5]. We
therefore compared the present data with the recently reported
whole blood gene-expression profiles from 99 patients with
multiple sclerosis [27]. Employing the k-nearest neighbor class
prediction approach, using the 80-gene list, none of the multiple
sclerosis patients were classified as having HAM/TSP. Thus, the
signature distinguished HAM/TSP from the clinically similar
condition multiple sclerosis (Figure 3 A).
Over-expression of IFN-stimulated genes in patients with
HAM/TSP
To explore the biological function of the observed transcriptional
changes in HAM/TSP, we employed a modular analysis framework
[28] that compares transcript abundance between patients and
healthy control subjects in 28 groups (‘‘modules’’) of co-regulated
genes, the majority of which have been shown to reflect specific cell
populations or biological processes. The modular blood signature
(Figure 3 B) revealed an over-expression of IFN-stimulated genes in
HAM/TSP that was absent in asymptomatic virus carriers (module
M3.1). Differentially expressed genes included key proteins of IFN
signaling (STAT1, STAT2), genes associated with antigen processing
(TAP-1), cell migration (CXCL10) and the innate antiviral response
(IFI35). Transcriptional changes in the IFN-stimulated genes were
reproduced in the test set and were independent of proviral load
(Figure S2).
Figure 1. Canonical pathway analysis of the 542-gene blood transcriptional signature of HTLV-1 infection. (A) The biological pathway
affiliation of the genes was identified using Ingenuity Systems Pathway Analysis software (Ingenuity Systems Inc.). The graph displays the top 10
identified pathways. The 542 genes were strongly associated with p53-mediated signaling (P = 0.000186). Orange squares indicate the ratio of the
number of genes from the dataset that map to the canonical pathway. The solid blue bars correspond to the P-value representing the probability
that the association between the genes and the identified pathway occurs by chance alone (calculated by Fisher’s exact test with Benjamini-
Hochberg multiple testing correction, given as a log P-value). The involvement of the p53 signaling pathway was statistically significant even at the
level of individual genes. The mRNA levels of genes mediating (B) cellular DNA damage responses, (C) cell cycle arrest and (D) apoptosis were
significantly altered in patients with HAM/TSP. Box plot represent median 6 1.5 IQR. P-values were calculated using a two-tailed Mann-Whitney test;
Ctrl: n = 9, AC: n = 20, HAM/TSP: n = 10.
doi:10.1371/journal.ppat.1002480.g001
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A separate pathway-focused analysis of the 80-gene blood
transcriptional signature, using Ingenuity Systems Pathway
Analysis software, independently confirmed IFN signaling as the
dominant pathway associated with HAM/TSP (Figure 3 C). Here,
IFN-stimulated transcripts constituted 29% (23 genes) of the 80
genes, and included genes inducible by both type I (IFN- a/b) and
type II (IFN-c) IFNs.
To test whether the expression of the distinct subset of IFN-
stimulated genes in the 80-gene blood transcriptional signature
reflects common immune responses observed in several diseases,
we quantified expression of these genes in bacterial and other
inflammatory diseases (Figure S3 A). No significant transcriptional
changes in IFN-stimulated genes were detected in patients with
multiple sclerosis, Still’s disease or individuals infected with
Staphylococcus or group A Streptococcus. Expression levels in
adults or children with systemic lupus erythematosus (SLE) were
similar to those observed in patients with HAM/TSP; however,
both adult and pediatric SLE differentially expressed 92–95% of
IFN-stimulated genes comprised in the IFN module (M3.1), whilst
the IFN response in patients with HAM/TSP was limited to a
small subset (Figure S3 B). We conclude that in contrast to the
broad IFN-stimulated gene expression pattern in SLE, the IFN-
mediated immune response in patients with HAM/TSP is
restricted to a distinct subset of IFN-stimulated genes.
To confirm that the observed HAM/TSP transcriptional
signature resulted from differential transcriptional regulation rather
than differences in cell composition, we quantified frequencies of
peripheral leukocyte subsets in HTLV-1 carriers and control
subjects by flow cytometry. No significant differences in the
abundance of antigen-presenting or major effector cell populations
were observed between the study groups (Figure S4).
The HAM/TSP IFN-inducible signature is present in
monocytes and neutrophils
CD4+ T cells constitute the main reservoir for HTLV-1 in vivo.
To test whether the observed IFN-inducible signature was
restricted to HTLV-1-infected CD4+ T cells we selected genes
with the highest association with HAM/TSP (11 genes; see
Methods) and quantified their expression levels in separated blood
leukocyte populations by quantitative RT-PCR (Figure 4 A). The
IFN-inducible signature was present in neutrophils and monocytes
(Fisher’s method of combining probabilities: P = 0.0271 and
Figure 2. Presence of an 80-gene blood transcriptional signature in HAM/TSP. The blood expression levels of 80 genes differed between
patients with HAM/TSP and clinically asymptomatic HTLV-1 carriers and uninfected individuals. (A) Microarray training and (B) test set gene
expression profiles. Participants were clustered in hierarchical condition trees (Spearman correlation with average linkage) with each row
representing a single gene and each column an individual subject. Color scale indicates normalized expression values and colored boxes below the
trees indicate the individual’s clinical classification (study group). ACs with high or low HTLV-1 proviral load were not distinguished by color because
their results did not differ significantly either in hierarchical clustering or WMDH analysis. (C) Quantification of transcriptional changes in the 80 genes.
The ‘weighted molecular distance to health’ metric [12] was calculated for each patient and the median compared between study groups (Mann-
Whitney test). (D) Correlation between the transcriptional signature and the clinical severity of HAM/TSP. Extent of impaired mobility was assessed by
patients’ performance in the 10-meter walk test (see methods). Graphs (C) and (D) comprise data of the training and test set. PVL=HTLV-1 proviral
load. Box plot represent median 6 1.5 IQR. The P-values were calculated using a two-tailed Mann-Whitney test.
doi:10.1371/journal.ppat.1002480.g002
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P=0.0260 respectively) but not in CD4+ or CD8+ T cells (P = 0.3
and P= 0.1, respectively, Figure 4 A). The mRNA levels of four
representative IFN-stimulated genes (STAT1, CD64, FAS and
CXCL10, Figure S5) correlated well with their protein levels, thus
confirming the presence of the IFN-inducible signature at the
protein level. Furthermore, increased protein levels of STAT1, a
key molecule in IFN signaling, were detected by flow cytometry in
all peripheral blood effector cell populations from patients with
Figure 3. The HAM/TSP transcriptional signature comprises IFN-stimulated genes and is not present in multiple sclerosis. (A) The 80-
gene transcriptional signature discovered in HAM/TSP was not present in patients with multiple sclerosis (MS). Datasets were normalized to their own
controls (training set: HAM/TSP n= 10, Ctrl n = 9; test set: HAM/TSP n= 10, Ctrl n = 8; multiple sclerosis data set [27]: patients n = 99, Ctrl n = 45). (B)
Modular analysis approach. Gene expression levels were compared between HTLV-1-positive study groups and healthy control subjects on a module-
by-module basis [28]. Modules correspond to previously identified co-regulated gene clusters that were assigned biological functions by unbiased
literature profiling (see legend grid on the right). Over-abundance of transcripts in a module is depicted in red, under-abundance in blue. The
intensity of the dot corresponds to the percentage of genes in the respective module that are significantly differentially expressed between the study
groups. (C) Canonical pathway analysis of the 80-gene HAM/TSP signature (Ingenuity Systems Pathway Analysis software). Orange squares represent
the ratio of the number of genes present in the transcriptional signature versus all genes in the pathway. Solid blue bars correspond to the P-value
representing the probability that the association between the genes and the identified pathway is due to chance alone (Fisher’s exact test with
Benjamini-Hochberg multiple testing correction, given as log P-value).
doi:10.1371/journal.ppat.1002480.g003
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HAM/TSP, but not in ACs or uninfected controls (Figure 4 B).
These results suggest that the observed IFN-inducible transcrip-
tional signature in whole blood did not result from direct
activation of IFN-mediated anti-viral pathways in infected CD4+
T cells but rather that all cell types had been systemically exposed
to IFNs in vivo.
Molecular basis of the IFN-inducible signature in HAM/
TSP
To identify the molecular basis of the IFN-inducible signature,
we tested for abnormal production of IFNs and abnormal
responses to IFNs in patients with HAM/TSP. In agreement with
previous findings [29,30] we found that protein levels of the IFN-
c-inducible chemokine CXCL10 were significantly increased in
plasma from patients with HAM/TSP compared to ACs;
however, IFN-a2, IFN-b, IFN-l and IFN-c protein levels were
not elevated (Figure S6). There were no differences in the
production of IFN-a by stimulated plasmacytoid dendritic cells in
short-term whole blood ex vivo assays. The frequency of CD8+ T
cells producing IFN-c in patients with HAM/TSP was greater
than that in uninfected controls, but did not differ significantly
from the frequency observed in ACs (Figure S7).
Next we analyzed molecules of the IFN signaling pathway that
are involved in IFN-responsiveness. Surface expression levels of
IFN-a and IFN-c receptors on peripheral leukocyte populations
were similar in all study groups (Figure S8). We then measured
phosphorylated STAT1 (p-STAT1) by flow cytometry as a marker
of activation of the IFN signaling pathway at the single-cell level.
Stimulation with recombinant IFNs (particularly IFN-c) led to an
increase in p-STAT1 levels in all study groups (Figure 5 A–B).
Patients with HAM/TSP had higher STAT1 protein baseline
levels which after IFN stimulation resulted in significantly higher
p-STAT1 levels compared to ACs or uninfected controls.
Expression of STAT1 itself is upregulated by IFNs [31]; it is
likely that exposure to IFNs in vivo induces higher STAT1 protein
and thus p-STAT1 levels which makes leukocytes from patients
with HAM/TSP more sensitive to IFNs.
Effect of IFN-a and IFN-c on HTLV-1 Tax, Gag and HBZ
expression
IFNs activate several intracellular antiviral responses and are
typically associated with a beneficial effect on the outcome of viral
infection [32]. To examine the effect of IFNs on HTLV-1 protein
expression, we quantified expression of HTLV-1 Tax and Gag after
treatment with exogenous IFN-a and IFN-c. Interestingly, whilst
IFN-a treatment partially inhibited the expression of the HTLV-1
protein Gag, it could not suppress production of the pleiotropic viral
transcriptional transactivator Tax (Figure 5 C–D). In contrast, IFN-
c treatment did not alter the expression of either Gag or Tax
proteins in infected CD4+ T cells (Figure S9 A, B). Exogenous IFN-
a and IFN-c increased HBZ mRNA levels but this did not reach
statistical significance (Figure 5 E; Figure S9 C, D).
Figure 4. Over-expression of IFN-stimulated genes in patients with HAM/TSP. (A) The mRNA levels of the 11 genes most strongly
associated with presence of HAM/TSP in whole blood and separated peripheral blood immune cell populations as quantified by real-time PCR (P-
value: Fisher’s method of combining probabilities). Ctrl: n = 4, HAM/TSP: n = 4. (B) STAT1 protein levels in blood leukocyte populations. Whole blood
samples were stained for markers of leukocyte populations; intracellular expression of STAT1 was assessed by flow cytometry. P-values were
calculated using a two-tailed Mann-Whitney test with P,0.05 HAM/TSP versus *controls or $AC. Data represent mean 6 SEM, Ctrl: n = 6, AC: n = 6,
HAM/TSP: n = 6.
doi:10.1371/journal.ppat.1002480.g004
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Discussion
Despite the growing understanding of the mechanisms of
HTLV-1 persistence, little is known about the pathogenesis of
HAM/TSP and importantly, what distinguishes hosts who
develop the disease from those who remain asymptomatic. The
aim of this study was to identify biological pathways and molecules
in whole blood gene expression profiles of asymptomatic HTLV-1
carriers and patients with HAM/TSP to generate new hypotheses
on the mechanisms of viral persistence and the pathogenesis of
HAM/TSP pathology.
We found that the presence of HAM/TSP was associated with
over-expression of a distinct subset of IFN-stimulated genes in
circulating leukocytes. The IFN-inducible signature was absent in
healthy HTLV-1 carriers and correlated positively with the clinical
severity of the inflammatory disease. Gene expression signatures
may reflect either differences in the frequencies of specific cell
populations or a difference in gene expression at the single-cell
level. We observed no significant differences in the frequencies of
the blood cell populations (Figure S4): we conclude that the
observed IFN-inducible signature resulted from a difference in the
intensity of expression of IFN-stimulated genes at the single-cell
level.
Expression of IFN-stimulated genes was evident in neutrophils
and monocytes, but not in T cells, which are the cellular reservoir of
HTLV-1 in vivo [15]. It is therefore likely that the HAM/TSP-
specific transcriptional profile originated from exposure to IFNs in
vivo rather than direct activation of the IFN-response pathway in
infected cells. The IFN-stimulated genes identified in HAM/TSP
can be induced by both type I and type II IFNs [33] and we did not
detect abnormal plasma levels of type I or type II IFNs in patients
with HAM/TSP, perhaps because of their short half-lives in blood
[34]. However, CD8+ T cells from patients with HAM/TSP
produced high levels of IFN-c in response to a non-specific stimulus
ex vivo, which may reflect higher local production of IFN-c in vivo.
IFN-stimulated genes have been shown to mediate potent
antiviral and neuroprotective effects [32,35]. However, several
recent studies have implicated IFNs in the pathogenesis of
autoimmune disorders such as rheumatoid arthritis [36], systemic
lupus erythematosus [37], systemic sclerosis [38] and Sjo¨gren’s
syndrome [39]. It has been hypothesized that IFNs trigger
Figure 5. Cellular and viral responses to IFN in HTLV-1 carriers. STAT1-P(Y701) phosphorylation in response to (A) IFN-a and (B) IFN-c was
quantified in whole blood by flow cytometry. Bar graphs represent the mean 6 SEM. P-values were calculated using a two-tailed Mann-Whitney test
with *P,0.05 versus controls, $P,0.05 versus AC; Ctrl: n = 6, AC: n = 6, HAM/TSP: n = 6. Effect of exogenous IFN-a on the expression of viral
transcriptional transactivator (C) Tax (P = 0.4263), (D) the structural protein Gag (P = 0.0112) and (E) HBZ mRNA (P = 0.0742). Tax and Gag protein levels
were assessed by flow cytometry, HBZ mRNA was quantified by real-time PCR. P-values were calculated using a paired Wilcoxon signed-rank test; Tax
and Gag protein: HAM/TSP: n = 11; HBZ mRNA: AC: n = 2, HAM/TSP: n = 7.
doi:10.1371/journal.ppat.1002480.g005
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autoimmunity by promoting the activation and survival of
autoreactive T and B cells in genetically predisposed individuals
[40]. However, there is little evidence for antigen-specific
autoreactivity in HAM/TSP [41]; instead, the risk of disease is
linked to high frequencies of poor quality antiviral cytotoxic T cells
[42]; i.e. low avidity of HTLV-1 antigen recognition and reduced
lytic efficiency. IFNs may contribute to immunopathological
processes in the central nervous system by stimulating and
propagating a detrimental immune response to HTLV-1; however,
the precise pathways responsible have yet to be determined.
Despite similarities in clinical presentation the gene expression
profiles of HAM/TSP and multiple sclerosis were distinct. The
IFN-inducible signature present in HAM/TSP was absent in
multiple sclerosis, suggesting that different pathogenetic mecha-
nisms contribute to the axonal damage observed in both diseases.
A recent study reported the expression of a subset of type I IFN-
stimulated genes in 50% of patients with a particular clinical
subtype of multiple sclerosis (relapsing-remitting) [43]. However,
in agreement with our findings there was little overlap between the
IFN-stimulated genes identified in HAM/TSP and the genes
whose expression was altered in multiple sclerosis. Furthermore,
we found that different subsets of IFN-stimulated genes are
actively expressed in other diseases with IFN-inducible signatures
(Figure S3). There are more than 300 known IFN-stimulated
genes, the individual actions of many of which are largely
uncharacterized. Thus, it is conceivable that there are cell-type-,
pathogen- and disease-specific patterns of IFN-stimulated gene
expression that contribute to a beneficial or detrimental outcome
of immunological processes.
Type I IFN therapy is effective in controlling certain persistent
viral infections [44], and there is evidence that it can slow down
disease progression in multiple sclerosis [45]. However, clinical
trials assessing the benefit of IFN-a and IFN-b therapy in the
treatment of HAM/TSP have been less successful [46]; few
patients showed any improvement and the overall clinical benefit
was limited. Although a beneficial net effect of systemically
administered IFN cannot be excluded, two findings in the present
study support the clinical observation that IFNs do not effectively
control HTLV-1 infection: (i) over-expression of IFN-stimulated
genes was not observed in healthy HTLV-1 carriers who efficiently
control the infection; (ii) while IFN-a reduced the expression of the
structural viral protein Gag as reported previously [47], we found
that IFN treatment did not affect the expression of the viral
transactivator protein Tax or HBZ mRNA. HTLV-1 Tax is
essential to the viral life cycle as it has been shown to drive viral
replication, promote host cell proliferation and viral cell-to-cell
spread [48,49]. HBZ has been shown to down-modulate Tax
function [50,51] whilst promoting infectivity and viral persistence
[52]. A recent study has linked elevated HBZ mRNA levels to
increased clinical severity of HAM/TSP [53]. We found that IFN
treatment increased HBZ expression but this observation did not
reach statistical significance. We conclude that although type I
IFN treatment may decrease the production of viral structural
complexes, i.e. capsids, it does not completely abrogate viral
activity and proliferation of infected cells. In addition, HTLV-1
viral proteins have been reported to manipulate and evade the
IFN response by suppressing interferon regulatory factors and up-
regulating suppressors of IFN signaling [16,54,55].
Perturbations of the p53 signaling pathway were evident in all
HTLV-1 infected individuals, irrespective of disease status. The
p53 signaling pathway prevents cell proliferation of genomically
unstable cells by promoting cell cycle arrest, senescence and
apoptosis [56]. Altered p53 signaling could reflect a highly active
immune response with rapid cell turnover and clonal expansion.
However, abnormal p53 signaling has been implicated in HTLV-
1-mediated leukemogenesis [49]. The p53 protein itself is usually
intact in HTLV-1 leukemic cells, but there is evidence that the
virus inhibits p53-induced anti-viral responses by targeting other
components of the p53 signaling pathway [57,58]. This hypothesis
is supported by our finding that HTLV-1-positivity was associated
with low mRNA levels of molecules involved in the detection of
DNA damage, i.e. the ataxia telangiectasia mutated protein
(ATM) and the DNA-dependent protein kinase (PRKDC). The
protein products of these genes sense dsDNA breaks due to viral
integration into the cell’s genome and induce cell cycle arrest and/
or apoptosis [59]. Decreased expression of ATM and PRKDC
could therefore facilitate the survival of genomically unstable
HTLV-1-infected cells and allow premature DNA replication in
the presence of genomic lesions, thus contributing to the oncogenic
potential of HTLV-1.
In summary, our study revealed that over-expression of a
specific subset of IFN-stimulated genes distinguishes patients with
HAM/TSP from asymptomatic HTLV-1 carriers, which indicates
an unexpected role of IFN-stimulated genes in the pathogenesis of
central nervous system inflammation in HTLV-1 infection. This
finding opens new avenues for research on HAM/TSP pathogen-
esis and new areas of therapeutic intervention.
Materials and Methods
Ethics statement
All study participants have given written informed consent.
Ethical approval for this study was obtained as follows: IRB
approval numbers: St Mary’s NHS Trust Local Research
Committee EC no. 02.31 (27.06.2002); National Research Ethics
Service, Oxfordshire REC C no. 09/H0606/106 (16.11.2009).
Study participants
Consenting participants attended the HTLV clinic at St Mary’s
Hospital, London, UK. Deterioration of mobility in patients with
HAM/TSP was assessed by a 10-meter timed walk (time taken to
walk 10 m with or without a walking aid). The extent of
deterioration was categorized as ‘mild’ (8–15 s; n = 5), ‘moderate’
(16–30 s; n= 6) or ‘severe’ (.30 s or use of a wheelchair; n = 6).
HTLV-1 proviral load measurement
HTLV-1 proviral load was measured as described previously [6]
and expressed as percentage of peripheral blood mononuclear cells
(PBMCs).
Sample processing and microarray analysis
Blood was collected in Tempus tubes (Applied Biosystems,
Foster City, CA, USA). Total RNA and cDNA were prepared as
described previously [12] and analyzed on HumanHT-12 V3 or
WG6 V3 expression BeadChip arrays (Illumina, San Diego, CA,
USA). Raw gene expression values were normalized per gene to
the median gene expression value across all samples and
supervised non-parametric analysis was carried out in GeneSpring
GX7.3.1 (Agilent Technologies, Edinburgh, UK). A series of filters
was applied to identify genes differentially expressed between ACs
and patients with HAM/TSP (Figure S2). To identify the genes
most strongly associated with HAM/TSP, we selected genes that
were .1.5-fold differentially expressed versus ACs in .50% of
patients with HAM/TSP (11 genes). To visualize transcriptional
patterns, an iterative agglomerative clustering method was applied
to gene lists (algorithm: Pearson correlation) and samples
(algorithm: Spearman correlation). Microarray data was deposited
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in the Gene expression Omnibus database (accession number
GSE29312).
Illumina HT12 V3 microarray data relating to other diseases
has been published previously and is publically available: multiple
sclerosis [27], Still’s disease [12], Staphylococcus or group A
Streptococcus infection [12], adult and pediatric systemic lupus
erythematosus [12].
Class prediction was performed within GeneSpring using the k-
nearest neighbor algorithm (neighbors = 10; P-value ratio cut
off = 0.65) or support vector machine (Gaussian radial basis,
diagonal scaling = 3).
Biological interpretation of transcriptional signatures
Canonical pathway analysis was performed using the web-based
Ingenuity Systems Pathway Analysis software (Ingenuity Systems
Inc., Redwood City, CA, USA). Modular transcriptional finger-
prints [28] for the HTLV-1-positive study groups were generated
comparing BeadStudio raw gene expression values to baseline
median expression values of uninfected controls for all genes
present in a module (Student t-test, P,0.05). The weighted
molecular distance to health (WMDH) was calculated as described
previously [12] to quantify global transcriptional changes relative
to a pre-determined baseline value.
IFN-stimulated transcripts in the 80-gene blood transcriptional
signature were identified using the Interferome database (www.
interferome.org) [33].
Isolation of separated cell populations, RNA extraction
and quantitative Real-Time PCR
Neutrophils (CD15+) followed by CD8+ T cells or monocytes
(CD14+) followed by CD4+ T cells were isolated from whole blood
using antibody-coupled magnetic whole blood beads (Miltenyi
Biotec, Bergisch Gladbach, Germany). RNA from blood and
isolated cell populations was purified using the QIAamp RNA
Blood Mini Kit (QIAGEN, Hilden, Germany).
Total cDNA was generated from 1 mg of RNA using the
SuperScript III First-Strand Synthesis Supermix (Invitrogen,
Paisley, UK). Custom Taqman Low Density Array cards (Applied
Biosystems, Carlsbad, CA, USA) comprised probes for the top 11
genes associated with HAM/TSP (Table S5) and six reference
genes for normalization (B2M, ACTB, HMBS, GNB2L1, RPLP0,
18S). qRT-PCR was performed on a 7900HT fast real-time system
(Applied Biosystems). Ct values were extracted and analyzed using
SDS2.3 software (Applied Biosystems).
Quantification of IFN concentrations in plasma
Plasma concentrations of IFNs were measured by Luminex
using a LEGENDplex assay kit according to the manufacturer’s
instructions (Bioplex, Biolegend, San Diego, USA). Bioactivity of
type I and III IFNs in plasma samples was assessed using the iLite
Human Interferon Alpha Kit (Neutekbio, Galway, Ireland).
Quantification of blood leukocyte populations and CD64
and FAS expression by flow cytometry
Fresh blood was stained with monoclonal antibodies for
population specific markers (neutrophils: CD45+CD142CD16+,
monocytes: CD45+CD14+CD162, B cells: CD45+CD19+CD20+, T
cells: CD45+CD3+CD4+ or CD8+, NK cells: CD45+CD32CD56+
CD16+) and CD64 or FAS antibodies for 15 min at room
temperature (RT). Following lysis of erythrocytes with BD FACS
Lysing solution (BD Biosciences, Franklin Lakes, NJ, USA), samples
were acquired on a CyAn ADP flow cytometer (Beckman Coulter,
Marseille, France) and analyzed using FlowJo software (TreeStar,
Ashland, USA). All antibodies were purchased from eBioscience,
Beckman Coulter, BD Pharmingen and Miltenyi Biotec.
Detection of IFN-a secretion and IFN-c production in
whole blood by flow cytometry
IFN-a secretion assay: blood samples were stimulated with
10 mM R-848 (TLR-7/8 agonist; Insight Biotech, Wembley, UK)
for 3 h at 37uC. IFN-a secreted by plasmacytoid dendritic cells
(BDCA-2+CD123+) was measured using the Miltenyi Human IFN-
a Secretion Assay Detection Kit. Intracellular IFN-c production:
blood samples were stimulated with 10 ng/ml PMA, 0.5 mg/ml
calcimycin (Sigma, Gillingham, UK) in the presence of monensin
(eBioscience, San Diego, CA, USA) for 4 h at 37uC and analyzed by
flow cytometry.
Quantification of IFN receptor surface expression in
whole blood by flow cytometry
Fresh whole blood samples were incubated with IFNGR2-
Fluorescein (R&D Systems, Minneapolis, MN, USA), IFNGR1-PE
(eBioscience) or IFNAR1-Fluorescein and IFNAR2-PE (PBL
Interferon Source, Piscataway, NJ, USA) and immune cell popu-
lation markers for 25 min at RT. Following lysis of erythrocytes
with BD FACS Lysing solution (BD Biosciences), samples were
acquired on a CyAn ADP flow cytometer (Beckman Coulter) and
analyzed using FlowJo software (TreeStar).
Detection of basal STAT1 protein levels and IFN-induced
STAT1 phosphorylation by flow cytometry
Heparinized whole blood was treated with 1000 IU/ml of
recombinant IFN-a2a or IFN-c (PBL Interferon Source) for
20 min at 37uC. Detection of STAT1 phosphorylation by flow
cytometry was adapted for whole blood following the specifications
refined by Chow and colleagues [60].
Effect of exogenous IFN on Tax and Gag protein and HBZ
mRNA expression
CD8+ T cells were depleted from PBMCs by positive selection
using antibody-coated magnetic microbeads (Miltenyi Biotec) to
prevent cytotoxic T cell-mediated killing of HTLV-1 expressing
cells. Cells were incubated in the presence of 100 IU/ML IFN-a,
100 IU/ml IFN-c or PBS in RPMI 1640 medium (Sigma)
supplemented with 10% FCS, 2 mM L-Glutamine, 100 U/ml
Penicillin and 100 mg/ml Streptomycin (Life Technologies) at 37uC
in 5% CO2. For HBZ mRNA expression cells were harvested after
0, 2, 4, 8, and 16 h and RNA extracted using the RNeasy kit
(QIAGEN, Hilden, Germany) according to the manufacturer’s
instructions. The cDNA was produced using the QuantiTect
Reverse Transcription kit (QIAGEN) and qRT-PCR was per-
formed in 96-well plates on a 7900HT fast real-time system (Applied
Biosystems). Primer sequences detected spliced HBZ mRNA:
forward primer 59-GGACGCAGTTCAGGAGGCAC-39, reverse
primer 59-CCTCCAAGGATAATAGCCCG-39. Ct values were
extracted and analyzed using SDS2.3 software (Applied Biosys-
tems). HBZ mRNA levels were normalised to endogenous GAPDH
levels (primers: forward 59-CTTTGGTATCGTGGAAGGACTC-
39, reverse 59-GTAGAGGCAGGGATGATGTTCT-39.
For Tax and Gag protein detection cells were fixed and
permeabilized after 16 h using the FoxP3 staining buffer set from
eBioscience and stained for CD3, CD4, CD8, HTLV-1 Tax (LT4
antibody) [61] and HTLV-1 Gag (Gin7 antibody) [62] and
analyzed by flow cytometry.
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Statistical analysis
Correlations were tested by Spearman’s rank-order and
differences between two study groups by Mann-Whitney U test.
Pairwise comparisons were tested using the Wilcoxon signed-rank
test. All tests were two-tailed. Box plots are depicted as median
with error bars within the 1.5 interquartile range (IQR); bar
graphs depict median with error bars representing the standard
error of the mean (SEM). Statistical programs used included SPSS
version 17; Microsoft Excel 2007; GeneSpring GX7.3.1 and the
DiagnosisMed package in R.
Supporting Information
Figure S1 Data dimension reduction by supervised non-
parametric analysis of the microarray training set.
(TIF)
Figure S2 Modular framework analysis of the HTLV-1
test set. Gene expression levels were compared between (A) ACs
or (B) patients with HAM/TSP and healthy control subjects on a
module-by-module basis (Student t-test, P,0.05). Over-expressed
genes are depicted in red, under-expressed genes in blue. The
intensity of the dots corresponds to the percentage of genes that
are significantly differentially expressed between the study groups.
A functional interpretation of the modules is provided in the
legend.
(TIF)
Figure S3 Expression of a distinct subset of IFN-
stimulated genes distinguishes HAM/TSP from other
diseases. (A) Transcriptional changes for all IFN-stimulated
genes comprised in the 80-gene blood transcriptional signature
were calculated using the WMDH metric and compared between
patients with HAM/TSP (patients n= 20, control n= 17), multiple
sclerosis (MS; n= 99, control n = 45), Still’s disease (Still’s; n = 31,
control n= 22), individuals infected with Staphylococcus (n = 40,
control n= 12) or group A Streptococcus (n = 23, control n= 12)
and patients with adult (ASLE; n= 28, control = 15) or pediatric
systemic lupus erythematosus (PSLE; n= 82, control = 18). P-
values were calculated using a two-tailed Mann-Whitney test; box
plots represent median 6 1.5 IQR. (B) In contrast to patients with
SLE, transcriptional changes in patients with HAM/TSP were
limited to a small subset of IFN-stimulated genes. Based on list of
76 IFN-stimulated genes in module M3.1, non-parametric group
comparisons were performed between patients with HAM/TSP
and adult or paediatric systemic lupus erythematosus (ASLE and
PSLE). Numbers in brackets depict the number of genes that were
significantly different expressed between patients with the disease
and their respective healthy controls (two-tailed Mann Whitney
test, P,0.05).
(TIF)
Figure S4 Relative frequencies of peripheral blood cell
populations in HTLV-1-positive patients and healthy
controls. Cells from heparinised blood were stained with
monoclonal antibodies corresponding to well-characterised mark-
ers of antigen-presenting and effector cell populations. Following
lysis of red blood cells using the BD FACS Lysing solution, the
samples were analysed by flow cytometry. (A) plasmacytoid
dendritic cells, (B) myeloid dendritic cells, (C) monocytes, (D)
neutrophils, (E) B cells, (F) NK cells, (G) CD4+ T cells, (H) CD8+ T
cells, (I) CD42CD82 T cells; WBC=white blood cells. P-values
were calculated using a two-tailed Mann-Whitney test; Ctrl: n#6,
AC: n#9, HAM/TSP: n#9.
(TIF)
Figure S5 Validation of the IFN-inducible transcription-
al signature in HAM/TSP on the protein level. The
mRNA and protein levels of the IFN-stimulated genes (A, B)
STAT1, (C, D) CD64 and (E, F) FAS were quantified by real-time
PCR and flow cytometry on peripheral leukocyte populations.
Data represents mean 6 SEM; P-values were calculated using a
two-tailed Mann-Whitney test with*P,0.05; mRNA: Ctrl: n = 4,
HAM/TSP: n= 4; protein: Ctrl: n = 10, HAM/TSP: n= 10. (G)
Blood mRNA levels of CXCL10 correlated well with CXCL10
protein levels in plasma (Spearman correlation P-value = 0.0011).
AC: n= 13, HAM/TSP: n= 13.
(TIF)
Figure S6 Plasma concentrations of Type I, II and Type
III IFNs and CXCL10. Plasma was cleared of blood cells by
spin centrifugation and analyzed by luminex for concentrations of
(A) IFN- a, (B) IFN-b, (C) IFN-c, (D) IFN-l and the IFN-c-
inducible chemokine (E) CXCL10. P-values were calculated using
a two-tailed Mann-Whitney test. No Type I and Type III IFN
bioactivity was detected in plasma samples (data not shown). Ctrl:
n = 12, AC: n= 13, HAM/TSP: n= 13.
(TIF)
Figure S7 Production of IFN-a and IFN-c in HTLV-1
carriers. (A) IFN-a secretion by plasmacytoid dendritic cells
(pDCs) in whole blood in response to stimulation of TLR7 and
TLR8. Fresh blood was stimulated with 10 mM R-848 for 3 h
at 37uC. Secreted IFN-a was captured on the surface of pDCs and
quantified by flow cytometry. (B) Intracellular production of
IFN-c in CD8+ T cells after PMA/calcimycin stimulation. Fresh
blood was stimulated with 10 ng/ml PMA and 0.5 mg/ml
calcimycin in the presence of monensin for 4 h at 37uC. Intra-
cellular production of IFN-c in CD8+ T cells was analyzed by
flow cytometry. Histograms are gated on (A) pDCs or (B) CD8+ T
cells; unstimulated controls are indicated as grey shaded area,
stimulated samples are indicated by a solid black line. Data
represents mean 6 SEM; P-values were calculated using a two-
tailed Mann-Whitney test; Ctrl: n = 6, AC: n= 6, HAM/TSP:
n= 6.
(TIF)
Figure S8 Surface expression of IFN receptors. Heparin-
ised blood samples were analysed by flow cytometry after staining
with monoclonal antibodies corresponding to leukocyte popula-
tions and (A) IFN-a receptor 1 (IFNAR1), (B) IFN-a receptor 2
(IFNAR2), (C) IFN-c receptor 1 (IFNGR1) or (D) IFN-c receptor
2 (IFNGR2). No significant changes in IFN receptor abundance
were detected between the study groups. Data represents mean 6
SEM; P-values were calculated using a two-tailed Mann-Whitney
test; Ctrl: n = 6, AC: n= 5, HAM/TSP: n= 4.
(TIF)
Figure S9 Effect of exogenous IFN on Tax and Gag
protein and HBZ mRNA expression. Fresh PBMCs were
depleted of CD8+ T cells and incubated for 16 h in the absence or
presence of 100 IU/ml IFN-c (Tax, Gag, HBZ) or IFN-a (HBZ).
(A) Tax (P= 0.4263) and (B) Gag (P= 0.5561) protein levels were
not altered by IFN-c treatment as measured by flow cytometry. (C)
HBZ mRNA levels were quantified by real-time PCR after 0, 2, 4,
8 and 16 h in response to IFN-a and IFN-c treatment. Graph
depicts mean 6 SEM; AC: n= 2, HAM/TSP: n= 2. (D) Table
depicts the average HBZ mRNA fold change after 16 h incubation
with IFNs. P-values were calculated using a Wilcoxon signed-rank
test. AC: n= 2, HAM/TSP: n= 7.
(TIF)
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Table S1 Demographics characteristics of uninfected
and HTLV-1-positive individuals in the (A) microarray
training and (B) test set.
(DOC)
Table S2 List of the 542 transcripts deregulated in
HTLV-1 infection.
(DOC)
Table S3 List of 80 transcripts deregulated in HAM/
TSP.
(DOC)
Table S4 Class prediction analysis of the 80-gene
transcriptional signature.
(DOC)
Table S5 List of probes used in custom Taqman low
density array.
(DOC)
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